 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2025, vol. 31, issue1
Subject Area: Medicine
-
DOI: 10.5272/jimab.2025311.6025
Published online: 20 Febrary 2025
Original article
J of IMAB. 2025 Jan-Mar;31(1):6025-6028
THE ROLE OF SOME INFLAMMATORY BIOMARKERS IN ASSESSING THE SEVERITY AND COURSE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Elena Borisova1
, Snezhanka Ivankovska1, Plamen Pavlov1, Svetla Blazheva2, Pavlina Glogovska3,
1)Department of Pulmonology and Phthysiology, Faculty of Medicine, Medical University - Pleven, Bulgaria.
2)Department of Immunology and Allergology, Faculty of Medicine, Medical University Pleven, Bulgaria.
3)Department of Propaedeutics of Internal Diseases, Faculty of Medicine, Medical University - Pleven, Bulgaria.
ABSTRACT:
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with pulmonary and extrapulmonary involvement. The inflammatory process plays a role in the pathogenesis of COPD. Inflammation is local and systemic, involving many inflammatory biomarkers, mediators and cytokines.
Objective: To determine the relationship between the severity and course of COPD with the levels of some inflammatory biomarkers.
Materials and methods: Retrospective study in 85 outpatients with COPD for a six-month period in 2023. Patients were stratified by disease severity according to GOLD 2019 criteria.
COPD exacerbations in the previous year were tracked.
The levels of the main markers of inflammation in COPD - leukocytes, neutrophils, CRP and uric acid were studied, and those that were less frequently monitored in medical practice - IL-6, IL-8 and vitamin D. We studied their relationship with the severity and the course of the disease.
The survey data were processed using STATGRAPHICS PLUS and EXCELL for Windows.
Results: We established: positive correlations between: the severity of COPD and high values of leukocytes (p=0.002) and uric acid (Pearsson p<0.05); exacerbations and high leukocyte values (p=0.01); the higher point score of CAT and high values of leukocytes ( p=0.008 ) and IL p<0.05); leukocyte levels and mMRC score (p=0.0005), there is a negative correlation between vitamin D and mMRC ( p=0.02 ).
Conclusion: Elevated levels of inflammatory biomarkers are associated with systemic inflammation in COPD, but there is no proven specific biomarker for the severity and course of the disease.
Keywords: COPD, inflammation, biomarkers, exacerbations,
- Download FULL TEXT /PDF 622 KB/
Please cite this article as: Borisova E, Ivankovska S, Pavlov P, Blazheva S, Glogovska P. The role of some inflammatory biomarkers in assessing the severity and course of chronic obstructive pulmonary disease. J of IMAB. 2025 Jan-Mar;31(1):6025-6028. [Crossref - 10.5272/jimab.2025311.6025]
Correspondence to: Elena Borisova, MD. Department of Propaedeutics of Internal Diseases, Faculty of Medicine, Medical University, Pleven; 8A, George Kochev Str., Pleven 5800, Bulgaria; E-mail: elenaborissova@abv.bg
REFERENCES:
1. Cazzola M, Blasi F. There is still no established and accepted definition of COPD. Respir Med. 2023Aug; 214:107262. [PubMed]
2. Bezerra FS, Lanzetti M, Nesi RT, Nagato AC, Silva CPE, Kennedy- Feitosa E, et al. Oxidative Stress and Inflammation in Acute and Chronic Lung Injuries. Antioxidants (Basel). 2023 Feb 21;12(3):548. [PubMed]
3. Meshi B, Vitalis TZ, Ionescu D, Elliott WM, Liu C, Wang XD, et al. Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am J Respir Cell Mol Biol. 2002 Jan;26(1):52-7. [PubMed]
4. Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax. 2002 Jul;57(7):590-5. [PubMed]
5. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 May 15;185(10):1065-72. [PubMed]
6. Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med. 2004 Oct;1(1):e8. [PubMed]
7. Stratev V, Petkova D, Dimitrova V, Petev J. Comorbidities of COPD in Bulgarian Patients - Prevalence and Association with Severity and Inflammation. Folia Med (Plovdiv). 2018 Mar 1;60(1):102-109 [PubMed]
8. Lu FY, Chen R, Li N, Sun XW, Zhou M, Li QY, et al. Neutrophil-to-Lymphocyte Ratio Predicts Clinical Outcome of Severe Acute Exacerbation of COPD in Frequent Exacerbators. Int J Chron Obstruct Pulmon Dis. 2021 Feb 17; 16:341-349 [PubMed]
9. Yang H, Wang Z, Xiao S, Dai C, Wen X, Wu F, et al. Association Between Serum Uric Acid and Lung Function in People with and without Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2022 May 5; 17:1069-1080. [PubMed]
10. Cazzola M, Matera MG, Calzetta L, Rogliani P. Biologics in asthma and chronic obstructive pulmonary disorder. Respiratory Pulmonary Disease. 2022 Jul 26;7:8-14 [Internet]
11. Jasper AE, McIver WJ, Sapey E, Walton GM. Understanding the role of neutrophils in chronic inflammatory airway disease. F1000 Res. 2019 Apr 26;8:F1000 Faculty Rev-557. [PubMed]
12. Hassan A, Jabbar N. C-reactive Protein as a Predictor of Severity in Chronic Obstructive Pulmonary Disease: An Experience From a Tertiary Care Hospital. Cureus. 2022 Aug 21;14(8):e28229 [PubMed]
13. Francis NA, Gillespie D, Wootton M, White P, Bates J, Richards J, et al. Clinical Features and C-Reactive Protein as Predictors of Bacterial Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2020 Dec 1;15:3147-3158 [PubMed]
14. Li H, Chen Y. Serum uric acid level as a biomarker for chronic obstructive pulmonary disease: a meta-analysis. J Int Med Res. 2021 Jan;49(1):300060520983705. [PubMed]
15. Hussein, FGM, Mohammed, RS, Khattab, RA, Al-Sharawy LA. Serum interleukin-6 in chronic obstructive pulmonary disease patients and its relation to severity and acute exacerbation. Egypt J Bronchol. 2022 Feb;16:10. [Crossref]
16. Huang H, Huang X, Zeng K, Deng F, Lin C, Huang W. Interleukin-6 is a Strong Predictor of the Frequency of COPD Exacerbation Within 1 Year. Int J Chron Obstruct Pulmon Dis. 2021 Oct 28;16:2945-2951 [PubMed]
17. Prudente R, Ferrari R, Mesquita C, Machado L, Franco E, Godoy I, et al. Follow-Up of Interleukin 6 in Chronic Obstructive Pulmonary Disease - Complementary Results from Previous Studies. Int J Chron Obstruct Pulmon Dis. 2021 Nov 3;16:3019-3026 [PubMed]
18. Pantazopoulos I, Magounaki K, Kotsiou O, Rouka E, Perlikos F, Kakavas S, et al. Incorporating Biomarkers in COPD Management: The Research Keeps Going. J Pers Med. 2022 Mar 1;12(3):379 [PubMed]
19. Zhang J, Bai C. The Significance of Serum Interleukin-8 in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Tanaffos. 2018 Jan;17(1):13-21. [PubMed]
20. Fu L, Fei J, Tan ZX, Chen YH, Hu B, Xiang HX, et al. Low Vitamin D Status Is Associated with Inflammation in Patients with Chronic Obstructive Pulmonary Disease. J Immunol. 2021 Feb 1;206(3):515-523. [PubMed]
Received: 03 September 2024
Published online: 20 February 2025